The authors hypothesize that JAK1/2 inhibitors AZD1480 and CYT387 can effectively inhibit growth of canine DLBCL in vitro. They aim to assess the antitumor activity of AZD1480 and CYT387 in canine DLBCL and to determine the underlying mechanisms of action.
The design was an in vitro study of canine lymphoma cell growth, proliferation, and apoptosis by viability, proliferation and apoptosis assays.
A significant decrease in viable canine lymphoma cells was observed after AZD1480 and CYT387 treatments.
In addition, AZD1480 and CYT387 treatment resulted in decreased lymphoma cell proliferation and increased early apoptosis.
AZD1480 and CYT387 inhibit canine lymphoma cell growth in a dose-dependent manner.
Our findings justify further phase I/II clinical investigations of the safety and efficacy of JAK1/2 inhibitors in canine DLBCL and suggest new opportunities for novel anticancer therapies
Source: Lu, Z., Hong, C.C., Jark, P.C., Assumpção, A.L.F.V., Bollig, N., Kong, G. and Pan, X. (2017), JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation. Journal of Veterinary Internal Medicine. doi: 10.1111/jvim.14837
|
